Jefferson Bridge Capital Invests $1.74M in Johnson & Johnson

The investment firm adds to its position in the healthcare giant's stock.

Apr. 11, 2026 at 9:37am

Got story updates? Submit your updates here. ›

A highly detailed, black-and-white image of the inner workings of a complex banking or financial mechanism, conveying a sense of industrial power and institutional stability.An extreme close-up of the intricate machinery that powers the financial systems behind major healthcare companies like Johnson & Johnson.New Brunswick Today

Jefferson Bridge Capital LLC purchased a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,399 shares of the company's stock, valued at approximately $1,738,000.

Why it matters

This investment highlights the continued institutional interest in Johnson & Johnson, one of the world's largest and most diversified healthcare companies. As a major player in pharmaceuticals, medical devices, and consumer health products, J&J's stock is seen as a stable, long-term holding for many investors.

The details

According to the 13F filing, Jefferson Bridge Capital's new position in Johnson & Johnson comprises 1.7% of its total investment portfolio, making the stock its 23rd largest holding. The purchase comes as J&J shares have risen over the past year, boosted by the company's strong financial performance and pipeline of new products.

  • The 13F filing covers the 4th quarter of 2025.

The players

Jefferson Bridge Capital LLC

An investment management firm that purchased a new position in shares of Johnson & Johnson.

Johnson & Johnson

A multinational healthcare company that develops, manufactures, and markets pharmaceutical, medical device, and consumer health products.

Got photos? Submit your photos here. ›

The takeaway

This investment by Jefferson Bridge Capital underscores the continued appeal of Johnson & Johnson's diversified healthcare business model and its status as a blue-chip stock for long-term investors. As the company navigates challenges like patent expirations and pricing pressures, its strong brand, pipeline, and financial resources make it an attractive target for institutional investors.